Understanding the relationship between GSK-3 and Alzheimer’s disease: a focus on how GSK-3 can modulate synaptic plasticity processes
- 1 May 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 13 (5) , 495-503
Abstract
Originally discovered because of its role in the regulation of glucose metabolism, GSK-3 is now widely recognized as a crucial player in many cellular functions. Control of GSK-3 activity occurs by complex mechanisms that are each dependent upon specific signaling pathways. Furthermore, GSK-3 dysfunction has been linked to a number of pathologies, including Alzheimer's disease (AD). In particular, the involvement of GSK-3 in several key pathophysiological pathways leading to AD and neurodegenerative diseases has placed this enzyme in a central position in this disorder. In this article, the authors will specifically focus on the role of this enzyme as a key regulator of synaptic plasticity and how alterations in the GSK-3 synaptic functions may be a major factor in AD and other neurodegenerative disorders.Keywords
This publication has 108 references indexed in Scilit:
- Functional significance of glycogen synthase kinase-3 regulation by serotoninCellular Signalling, 2012
- Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathiesNature Reviews Drug Discovery, 2009
- Blocked Inhibitory Serine-Phosphorylation of Glycogen Synthase Kinase-3α/β Impairs In Vivo Neural Precursor Cell ProliferationBiological Psychiatry, 2009
- Transmission and spreading of tauopathy in transgenic mouse brainNature Cell Biology, 2009
- Αβ Hinders Nuclear Targeting of AICD and Fe65 in Primary Neuronal CulturesJournal of Molecular Neuroscience, 2009
- Mechanisms of tau-induced neurodegenerationActa Neuropathologica, 2009
- Association of GSK3B With Alzheimer Disease and Frontotemporal DementiaArchives of Neurology, 2008
- Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behaviorBehavioural Brain Research, 2008
- The role of GSK‐3 in synaptic plasticityBritish Journal of Pharmacology, 2008
- GAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 CarriersNeuron, 2007